Entacapone Teva

entacapone

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Entacapone Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Entacapone Teva.

What is Entacapone Teva?

Entacapone Teva is a medicine that contains the active substance entacapone. It is available as brown tablets (200 mg).

Entacapone Teva is a ‘generic medicine’. This means that Entacapone Teva is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Comtess.

What is Entacapone Teva used for?

Entacapone Teva is used to treat patients with Parkinson’s disease. Parkinson’s disease is a progressive brain disorder that causes shaking, slow movement and muscle stiffness. Entacapone Teva is used together with levodopa (either a combination of levodopa and benserazide or a combination of levodopa and carbidopa) when the patient is having ‘fluctuations’ towards the end of the period between two doses of their medication. Fluctuations happen when the effects of the medication wear off and symptoms re-emerge. They are linked with a reduction in the effects of levodopa, when the patient experiences sudden switches between being ‘on’ and able to move, and being ‘off’ and having difficulties moving about. Entacapone Teva is used when these fluctuations cannot be treated with the standard levodopa-containing combination alone.

The medicine can only be obtained with a prescription.

How is Entacapone Teva used?

Entacapone Teva is only used in combination either with levodopa and benserazide or with levodopa and carbidopa. It is taken as one tablet with each dose of the other medicine, up to a maximum of 10 tablets a day. It can be taken with or without food. When patients first add Entacapone Teva to their existing medication, they may need to take a lower daily dose of levodopa, either by changing how often they take it, or by reducing the amount of levodopa taken in each dose. Entacapone Teva can only be used with conventional combinations of levodopa. It should not be used with combinations that are ‘modified-release’ (when the levodopa is released slowly over a few hours).

How does Entacapone Teva work?

In patients with Parkinson’s disease, the cells in the brain that produce the neurotransmitter dopamine begin to die and the amount of dopamine in the brain decreases. The patients then lose their ability to control their movements reliably. The active substance in Entacapone Teva, entacapone, works to restore the levels of dopamine in the parts of the brain that control movement and coordination. It only works when it is taken with levodopa, a copy of the neurotransmitter dopamine that can be taken by mouth. Entacapone blocks an enzyme that is involved in the breakdown of levodopa in the body called catechol-O-methyl transferase (COMT). As a result, levodopa remains active for longer. This helps to improve the symptoms of Parkinson’s disease, such as stiffness and slowness of movement.

How has Entacapone Teva been studied?

Because Entacapone Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Comtess. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the benefits and risks of Entacapone Teva?

Because Entacapone Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

Why has Entacapone Teva been approved?

The CHMP concluded that, in accordance with EU requirements, Entacapone Teva has been shown to have comparable quality and to be bioequivalent to Comtess. Therefore, the CHMP’s view was that, as for Comtess, the benefit outweighs the identified risk. The Committee recommended that Entacapone Teva be given marketing authorisation.

Other information about Entacapone Teva

The European Commission granted a marketing authorisation valid throughout the European Union for Entacapone Teva to Teva Pharma B.V. on 18 February 2011. The marketing authorisation is valid for five years, after which it can be renewed.

For more information about treatment with Entacapone Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Entacapone Teva : EPAR - Summary for the public BG = bălgarski 03/03/2011  
Entacapone Teva : EPAR - Summary for the public ES = español 03/03/2011  
Entacapone Teva : EPAR - Summary for the public CS = čeština 03/03/2011  
Entacapone Teva : EPAR - Summary for the public DA = dansk 03/03/2011  
Entacapone Teva : EPAR - Summary for the public DE = Deutsch 03/03/2011  
Entacapone Teva : EPAR - Summary for the public ET = eesti keel 03/03/2011  
Entacapone Teva : EPAR - Summary for the public EL = elliniká 03/03/2011  
Entacapone Teva : EPAR - Summary for the public EN = English 03/03/2011  
Entacapone Teva : EPAR - Summary for the public FR = français 03/03/2011  
Entacapone Teva : EPAR - Summary for the public IT = italiano 03/03/2011  
Entacapone Teva : EPAR - Summary for the public LV = latviešu valoda 03/03/2011  
Entacapone Teva : EPAR - Summary for the public LT = lietuvių kalba 03/03/2011  
Entacapone Teva : EPAR - Summary for the public HU = magyar 03/03/2011  
Entacapone Teva : EPAR - Summary for the public MT = Malti 03/03/2011  
Entacapone Teva : EPAR - Summary for the public NL = Nederlands 03/03/2011  
Entacapone Teva : EPAR - Summary for the public PL = polski 03/03/2011  
Entacapone Teva : EPAR - Summary for the public PT = português 03/03/2011  
Entacapone Teva : EPAR - Summary for the public RO = română 03/03/2011  
Entacapone Teva : EPAR - Summary for the public SK = slovenčina 03/03/2011  
Entacapone Teva : EPAR - Summary for the public SL = slovenščina 03/03/2011  
Entacapone Teva : EPAR - Summary for the public FI = suomi 03/03/2011  
Entacapone Teva : EPAR - Summary for the public SV = svenska 03/03/2011  

This EPAR was last updated on 27/02/2014 .

Authorisation details

Product details

Product details for Entacapone Teva
NameEntacapone Teva
Agency product numberEMEA/H/C/002075
Active substance

entacapone

International non-proprietary name (INN) or common name

entacapone

Therapeutic area Parkinson Disease
Anatomical therapeutic chemical (ATC) code N04BX02
Generic

A generic medicine is a medicine which is similar to a medicine that has already been authorised (the 'reference medicine'). A generic medicine contains the same quantity of active substance(s) as the reference medicine. Generic and reference medicines are used at the same dose to treat the same disease, and they are equally safe and effective.

Publication details

Publication details for Entacapone Teva
Marketing-authorisation holder

Teva Pharma B.V.

Revision3
Date of issue of marketing authorisation valid throughout the European Union18/02/2011

Contact address:

Teva Pharma B.V.
Computerweg 10
NL-3542 DR Utrecht
The Netherlands

Product information

Product information

20/02/2014  Entacapone Teva -EMEA/H/C/002075 -N/0005

Name Language First published Last updated
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014
Entacapone Teva : EPAR - Product Information SV = svenska 03/03/2011 27/02/2014

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  
Entacapone Teva : EPAR - All Authorised presentations SV = svenska 03/03/2011  

Pharmacotherapeutic group

Anti-Parkinson drugs

Therapeutic indication

Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Entacapone Teva : EPAR - Procedural steps taken and scientific information after authorisation SV = svenska 07/02/2013 27/02/2014

Initial marketing-authorisation documents

Name Language First published Last updated
Entacapone Teva : EPAR - Public assessment report SV = svenska 03/03/2011  
CHMP summary of positive opinion for Entacapone Teva SV = svenska 26/11/2010  

Authorised

This medicine is approved for use in the European Union

More information on Entecapone Teva